Items related to Antibody-Drug Conjugates and Immunotoxins: From Pre-Clinical...
Antibody-Drug Conjugates and Immunotoxins: From Pre-Clinical Development to Therapeutic Applications (Cancer Drug Discovery and Development) - Hardcover
This volume gathers the leading research on antibody-drug conjugates and immunotoxins. Following a rigorous overview, the volume delves into focused sections on all aspects of ADCs and ITs from clinical development through to targeted therapeutic applications and the latest technologies.
"synopsis" may belong to another edition of this title.
From the Back Cover:
The concept of delivering ‘magic bullets’ to treat diseases was first proposed by Paul Erlich in the early 1900’s. The realization of this concept for the treatment of cancer occurred in the late 1990’s with the approval of monoclonal antibody therapies. The use of monoclonal antibodies conjugated (linked) to potent cytotoxic agents (antibody-drug conjugates, ADCs) for specifically delivering cytotoxics to cancer cells was an obvious extension of antibody-based therapy.
ADCs have been under intense investigation for several decades; progress, however, has been limited due to toxicity or lack of improved efficacy compared to unconjugated cytotoxics. More recently, linker technology and target selection have advanced such that several ADCs and immunotoxins are undergoing clinical testing or are approved for use. This important volume gives the latest and most comprehensive information on the topic, describing different types of ADCs and immunotoxins for both hematologic and solid malignancies. Finally, the volume highlights the promise that this technology holds for diverse types of human cancer.
"About this title" may belong to another edition of this title.
- PublisherHumana
- Publication date2012
- ISBN 10 1461454557
- ISBN 13 9781461454557
- BindingHardcover
- Number of pages388
- EditorPhillips Gail Lewis
Buy New
Learn more about this copy
US$ 167.19
Shipping:
FREE
Within U.S.A.
Top Search Results from the AbeBooks Marketplace
Seller Image
Antibody-Drug Conjugates and Immunotoxins: From Pre-Clinical Development to Therapeutic Applications (Cancer Drug Discovery and Development) [Hardcover ]
Published by
Humana Press
(2012)
ISBN 10: 1461454557
ISBN 13: 9781461454557
New
Hardcover
Quantity: 10
Seller:
Rating
Book Description Hardcover. Condition: new. Seller Inventory # 9781461454557
Buy New
US$ 167.19
Convert currency
Stock Image
Antibody-Drug Conjugates and Immunotoxins: From Pre-Clinical Development to Therapeutic Applications (Cancer Drug Discovery and Development)
Seller:
Rating
Book Description Condition: New. Seller Inventory # ABLIING23Mar2716030036715
Buy New
US$ 178.71
Convert currency
Stock Image
Antibody-Drug Conjugates and Immunotoxins: From Pre-Clinical Development to Therapeutic Applications
Published by
Springer
(2012)
ISBN 10: 1461454557
ISBN 13: 9781461454557
New
Hardcover
Quantity: > 20
Seller:
Rating
Book Description Condition: New. PRINT ON DEMAND Book; New; Fast Shipping from the UK. No. book. Seller Inventory # ria9781461454557_lsuk
Buy New
US$ 176.05
Convert currency
Seller Image
Antibody-Drug Conjugates and Immunotoxins
Published by
Springer New York Dez 2012
(2012)
ISBN 10: 1461454557
ISBN 13: 9781461454557
New
Hardcover
Quantity: 2
Seller:
Rating
Book Description Buch. Condition: Neu. This item is printed on demand - it takes 3-4 days longer - Neuware -The concept of delivering magic bullets to treat diseases was first proposed by Paul Erlich in the early 1900 s. The realization of this concept for the treatment of cancer occurred in the late 1990 s with the approval of monoclonal antibody therapies. The use of monoclonal antibodies conjugated (linked) to potent cytotoxic agents (antibody-drug conjugates, ADCs) for specifically delivering cytotoxics to cancer cells was an obvious extension of antibody-based therapy. ADCs have been under intense investigation for several decades; progress, however, has been limited due to toxicity or lack of improved efficacy compared to unconjugated cytotoxics. More recently, linker technology and target selection have advanced such that several ADCs and immunotoxins are undergoing clinical testing or are approved for use. This important volume gives the latest and most comprehensive information on the topic, describing different types of ADCs and immunotoxins for both hematologic and solid malignancies. Finally, the volume highlights the promise that this technology holds for diverse types of human cancer. 388 pp. Englisch. Seller Inventory # 9781461454557
Buy New
US$ 176.92
Convert currency
Seller Image
Antibody-Drug Conjugates and Immunotoxins
Published by
Springer New York
(2012)
ISBN 10: 1461454557
ISBN 13: 9781461454557
New
Hardcover
Quantity: > 20
Seller:
Rating
Book Description Gebunden. Condition: New. Dieser Artikel ist ein Print on Demand Artikel und wird nach Ihrer Bestellung fuer Sie gedruckt. Features up-to-date research Provides an exhaustive review of anti-body drug conjugate and immunotoxin targets Explores new technologies for site-specific conjugationThis volume gathers the leading research on antibody-drug conjugat. Seller Inventory # 4198751
Buy New
US$ 150.10
Convert currency
Seller Image
Antibody-Drug Conjugates and Immunotoxins : From Pre-Clinical Development to Therapeutic Applications
Published by
Springer New York
(2012)
ISBN 10: 1461454557
ISBN 13: 9781461454557
New
Hardcover
Quantity: 1
Seller:
Rating
Book Description Buch. Condition: Neu. Druck auf Anfrage Neuware - Printed after ordering - The concept of delivering magic bullets to treat diseases was first proposed by Paul Erlich in the early 1900 s. The realization of this concept for the treatment of cancer occurred in the late 1990 s with the approval of monoclonal antibody therapies. The use of monoclonal antibodies conjugated (linked) to potent cytotoxic agents (antibody-drug conjugates, ADCs) for specifically delivering cytotoxics to cancer cells was an obvious extension of antibody-based therapy. ADCs have been under intense investigation for several decades; progress, however, has been limited due to toxicity or lack of improved efficacy compared to unconjugated cytotoxics. More recently, linker technology and target selection have advanced such that several ADCs and immunotoxins are undergoing clinical testing or are approved for use. This important volume gives the latest and most comprehensive information on the topic, describing different types of ADCs and immunotoxins for both hematologic and solid malignancies. Finally, the volume highlights the promise that this technology holds for diverse types of human cancer. Seller Inventory # 9781461454557
Buy New
US$ 180.83
Convert currency